论文部分内容阅读
目的:探讨乳腺癌组织中新型微管结合蛋白Nu SAP的表达及临床意义。方法:选取乳腺癌组织50例,与相应癌旁正常乳腺组织37例(距癌灶5 cm以上)以及乳腺良性病变组织20例,分别用免疫组化与实时荧光定量PCR方法检测Nu SAP蛋白与m RNA的表达,分析Nu SAP表达与乳腺癌患者临床病理特征的关系。结果:Nu SAP蛋白与m RNA在乳腺癌组织中的表达水平明显高于癌旁正常组织和乳腺良性病变组织(均P<0.05);Nu SAP蛋白与m RNA的表达均在有腋窝淋巴结转移、HER-2表达阳性的乳腺癌组织中明显升高(均P<0.05),而与绝经状态、年龄以及ER、PR、Ki-67的表达无关(均P>0.05)。结论:Nu SAP在乳腺癌组织中的表达升高,且可能与乳腺癌的发生、发展及侵袭密切相关。
Objective: To investigate the expression and clinical significance of novel microtubule binding protein Nu SAP in breast cancer. Methods: Fifty cases of breast cancer and 37 cases of corresponding normal breast tissues (more than 5 cm away from the tumor) and 20 cases of benign breast lesions were enrolled in this study. Immunohistochemistry and real-time fluorescence quantitative PCR were used to detect the expression of Nu-SAP protein and m RNA expression analysis of Nu SAP expression and breast cancer patients with clinicopathological features. Results: The expression level of Nu SAP protein and m RNA in breast cancer tissues was significantly higher than that in adjacent normal tissues and benign breast lesions (all P <0.05). The expression of Nu SAP protein and m RNA in axillary lymph node metastasis, The expression of ER, PR and Ki-67 in HER-2 positive breast cancer tissues was significantly increased (all P <0.05), but not in menopausal status, age, and the expression of ER, PR and Ki-67. Conclusion: The expression of Nu SAP in breast cancer tissues may be closely related to the occurrence, development and invasion of breast cancer.